Targeted Oncology

FDA Grants Fast Track Designation to FRα-Targeting ADC for Ovarian Cancer

The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
BioWorld

Simcere Zaiming’s CDH6-binding ADC to enter clinic in US, China

Simcere Zaiming Pharmaceutical Co. Ltd. has announced clinical trial approvals in China and the U.S. for its CDH6-targeting antibody-drug conjugate (ADC), SIM-0505, for advanced solid tumors. A global ...
ascopubs.org

Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.

ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.